ArticleJournal of human genetics2026
Identification and characterisation of a novel homozygous KDM5A variant associated with severe axial hypotonia, seizures, and cardiac anomalies.
Article in Journal of human genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
KDM5A is a critical chromatin-modifying enzyme with lysine-specific demethylase activity and is highly expressed in brain tissues. Biallelic pathogenic variants in KDM5A are linked to KDM5A-related neurodevelopmental disorders, a rare disorder involving significant cognitive and motor impairments. We conducted a clinical and genetic evaluation of a patient with severe neurodevelopmental delay. Exome sequencing was performed to identify the genetic aetiology, followed by quantitative expression analysis to assess the functional impact of the identified variant on KDM5A mRNA levels. A novel homozygous KDM5A c.2836 C > T p.(Gln946Ter) variant was identified in the proband. Quantitative analysis showed a reduction in KDM5A expression. However, this decrease was not statistically significant. The patients displayed neuromotor developmental delay, severe axial hypotonia, absence of head control and mild upper-extremity spasticity. Additional findings included a history of seizures, facial dysmorphism and congenital heart disease. These findings expand the known clinical spectrum of El Hayek-Chahrour neurodevelopmental disorder (OMIM #620820), specifically highlighting severe motor impairment and complex cardiac involvement, including major aortopulmonary collateral artery, as previously undescribed features of this condition. The non-significant decrease in expression suggests that pathogenicity may arise from altered protein function rather than transcript depletion. Our findings underscore the importance of exome sequencing in delineating phenotypic variability in rare neurodevelopmental syndromes.
Identifiers
42618742What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.